Bladder Cancer Biobank, Canada

Certification Status: Approved

Registration Status: Completed

Objective: Bladder cancer (BC) is one of the most frequently diagnosed cancers in North America. Due to its high recurrence and mortality rates, BC is one of the most expensive and hard-to treat cancer as treatment options are limited and has not improved for decades. Radical cystectomy (RC), the conventional treatment for muscle invasive bladder cancer (MIBC), seriously impact patient quality of life (QoL) and is associated with a 5-year survival of only 50%. Importantly, >40% of the patients are not surgically fit and will die without receiving any definitive therapy. While radiation therapy (RT) represents an alternative, efficacy still needs to be improved as 30% of patients will require surgery and half will develop metastasis. At the molecular level, MIBC is a diverse disease, and it has been classified into molecular subtypes with heterogeneous clinical outcomes, making difficult to consistently diagnose patients and predict therapeutic prognosis. Thus, there is a growing need to identify predictive and prognostic biomarkers that can be used to efficiently improve the management of BC. In this regard, we have already established a REB approval biorepository for longitudinal collection of biological samples (tissues, blood, urine and stool) from BC patients, before and throughout multimodality treatments (neoadjuvant, surgery, chemoradiation, and immunotherapy).

Registered Biobank Name	Bladder Cancer Biobank
Biobank Leader	Jose Joao Mansure
Country	Canada
Email for biobank inquiries	jose.mansure@mail.mcgill.ca
Principal Investigator	Wassim Kassouf
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).